May 22, 2018 Price forecast | 2 weeks: -0.20% | 1 month: -1.33% | 3 months: 2.29%

RVNC stock forecast

Our latest prediction for Revance Therapeutics, Inc.'s stock price was made on the May 22, 2018 when the stock price was at 30.40$.

In the short term (2weeks), RVNC's stock price should underperform the market by -0.20%. During that period the price should oscillate between -7.29% and +9.44%.

In the medium term (3months), RVNC's stock price should outperform the market by 2.29%. During that period the price should oscillate between -17.12% and +28.75%.

About Revance Therapeutics, Inc.

Revance Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.

At the moment the company generates 3M USD in revenues.

On its last earning announcement, the company reported a loss of -3.97$ per share.

The book value per share is 5.68$

Revance Therapeutics, Inc. website

Three months stock forecastMay 22, 2018


Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
3M - -137M - -138M -3.97 - - 35M 5.68 -102M -6M -107M